BI-2852 is primarily utilized in the field of cancer research due to its ability to inhibit specific protein-protein interactions that are crucial for tumor growth and survival. It targets the interaction between KRAS and PDEδ, which plays a significant role in the localization and function of KRAS, a protein often mutated in various cancers. By disrupting this interaction, BI-2852 effectively hinders the oncogenic signaling pathways driven by mutant KRAS, making it a promising candidate for the development of targeted cancer therapies. Its application is particularly relevant in preclinical studies aimed at understanding KRAS-driven cancers and evaluating potential therapeutic strategies.